Last reviewed · How we verify
NCT05208567: LOVE
London Valvular Heart Disease and Reduced Ejection Fraction Detection in a Multi-ethnic Community Using Cardiac Ultrasound
trial testing Echocardiogram in Heart Valve Diseases in 500 participants. Currently enrolling.
2 August 2026
Quick facts
| Lead sponsor | Queen Mary University of London |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 14 March 2023 |
| Primary completion | 2 August 2026 |
| Estimated completion | 2 September 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Echocardiogram
Conditions studied
- Heart Valve Diseases — all drugs for Heart Valve Diseases →
- Left Ventricular Dysfunction — all drugs for Left Ventricular Dysfunction →
Sponsor
Queen Mary University of London
Who can join
65 and older, any sex, with Heart Valve Diseases or Left Ventricular Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Heart Valve Disease and Heart failure contribute to 25% of hospital emergency admissions while heart failure alone has become one of the most common causes for hospitalisation in people over the age of 65. The burden of disease is likely to be high in a multi-ethnic community but there is a paucity of data. Management of heart valve disease requires appropriate surveillance and timely surgery. Similarly heart failure management requires treatment with medications aimed at slowing prevention of symptoms and preventing premature death. The NHS long term plan priorities early detection and treatment of valve disease and heart failure in order to reduce the burden on emergency services and improve the health of the population. Diagnosis is made using cardiac ultrasound, however staff with the required skills-set are critically limited in the community. The investigators will train non-expert staff within primary care to perform abbreviated cardiac ultrasound to detect heart valve disease or heart failure. This will be opportunistic scanning to reduce healthcare footfall. All scans will be reviewed by an expert and the investigators will use the anonymised data to develop machine learning tools to begin working with academic partners to develop tools that can improve the reliability of diagnosis from ultrasound. The investigators hope to identify the proportion with the above conditions in a multi-ethnic community and assess the feasibility of developing a program where staff can be trained for community detection, streamlined referrals can be created bridging the gap between primary and secondary care, reducing hospital emergency admissions, while ensuring patients are managed optimally.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05208567
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Echocardiogram
Trials testing the same drug.
- NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
- NCT07058064 — WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring) · NA · recruiting
- NCT06927973 — Leveraging Exercise Stress Echocardiography for Heart Failure With Preserved Ejection Fraction · NA · completed
- NCT07132788 — Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass · active not recruiting
- NCT06622928 — Ventriculo-Arterial Coupling and Intra-Dialytic Changes in Hemodialysis Patients: Prognostic Insights · not yet recruiting
Other recruiting trials for Heart Valve Diseases
Currently open trials in the same condition.
- NCT07390903 — GLS in Difficult CPB Weaning · recruiting
- NCT07099859 — Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Unde · Phase 4 · recruiting
- NCT06215378 — Antagonization of Heparin With Protamine Sulfate After TAVI · Phase 3 · recruiting
- NCT06445231 — Echocardiography in Nursing Home · NA · recruiting
- NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
Other Queen Mary University of London trials
Trials by the same sponsor.
- NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
- NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
- NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
- NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
- NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05208567 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
- Last refreshed: 23 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05208567.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing